ClinicalTrials.gg
CompletedNCT01712204Updated May 22, 2018Results posted

A Proof-of-Concept Study of AC-201 to Prevent Gout Flares

A Phase 2 interventional study of Placebo and AC-201 in Gout Flares, sponsored by TWi Biotechnology, Inc.. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-05-22.

Sponsored by TWi Biotechnology, Inc. · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Hyperuricemia with a site in Taiwan — 1 open to participants now, 1 under way, none of them phase 3. Hyperuricemia · Taiwan.

Started
2013
with 1 other
Phase 2
4 of 14
none open now
Registered
3rd of 14
by date
Lead sponsor
1 of 14
TWi Biotechnology, Inc.

Among the 14 studies in Hyperuricemia with a site in Taiwan, this one is one of 2 that started in 2013, is one of 4 in phase 2, and was the 3rd registered.

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

Browse Hyperuricemia studies →

Open to participants now

1 of the 14 studies in Hyperuricemia with a site in Taiwan is open now. Recruiting first, the newest first:

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 29 Hyperuricemia studies recruiting now, 8 (28%) set no upper age limit and 13 (45%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hyperuricemia with a site in Taiwan, or all of them as a file.
02

Study summary

Initiation of ULT for gout increases the occurrence of acute gouty arthritis flares due to mobilization of urate from tissue deposits. IL-1β plays a key role in mediating the inflammatory response in gouty arthritis. The efficacy of IL-1β blockade in the prophylaxis of gouty flares during initiation of ULT has been validated in multiple trials of IL-1β inhibitor therapies. Therefore, it is believed that IL-1β is a relevant therapeutic target for gout flares. AC-201 is an IL-1β modulator indicated for the treatment of osteoarthritis with good safety record and very few contraindications to the co-morbidities commonly among gout patients. AC-201 has also been demonstrated to have uric acid-lowering effects in clinical trials. The favorable product profile of AC-201 overall provides a strong rationale for investigating its clinical utility as prophylaxis against flares when initiating ULT.

Read the detailed description

Clinical trials have demonstrated that anti-IL-1 agents (IL-1Ra, IL-1 Trap, and anti-IL-1β monoclonal antibody) can reduce the frequency of gout flares during the initial period of treatment with urate-lowering therapy and prevent of gout flares in gout patients with frequent flares. AC-201 is an oral IL-1 modulator but with a mechanism distinct from that of existing anti-IL-1 agents. The active metabolite of AC-201 has been shown in vitro and in vivo to inhibit the production and activity of IL-1, down-regulate IL-1 receptors, and increase IL1-Ra. Molecular research further suggests that these effects are mediated upstream via inhibition of MAPK signaling pathways and binding of NF-κB and AP-1 transcription factors that encode for a range of pro-inflammatory factors, including IL-1β, TNF-α, IL-6, IL-8, iNOS, and MMPs, which have been implicated in gout flares. AC-201 has also been demonstrated to have uric acid-lowering effects in clinical trials. The favorable product profile of AC-201 overall provides a strong rationale for investigating its clinical utility as prophylaxis against flares when initiating ULT.

03

Conditions studied

  • Gout Flares

Keywords

  • Prophylaxis of Acute Gout Flares
  • Urate-Lowering Therapy
  • Hyperuricemia
  • Gouty arthritis
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female age 20 to 80 years, inclusive
  • Meets at least 6 of the 12 American College of Rheumatology preliminary criteria (1977) for the classification of acute arthritis of primary gout, OR have proven tophus or documented monosodium urate (MSU) crystals in the joint fluid
  • Serum uric acid ≥7.5 mg/dL at screening
  • Experienced ≥2 gouty arthritis flares within one year prior to screening

Exclusion criteria

Exclusion Criteria:

  • Occurrence of a gouty arthritis flare ongoing at screening or during the screening period through baseline
  • Use of allopurinol, febuxostat, benzbromarone, probenecid, or sulfinpyrazone within 4 weeks prior to screening
  • Use of colchicine, , NSAIDs, or COX-2 inhibitors within 1 week prior to screening
  • Other (non-gout) chronic arthritis, acute inflammatory arthritis, diseases with arthritis, or any condition requiring chronic daily use of pain medication
  • History of allergy to any components of study medication, including diacerein
  • Allergy, , or intolerance to febuxostat
  • Contraindication or allergy to NSAIDs
  • Severe renal impairment
  • Any prior use of biologic anti-inflammatory therapy, such as IL-1 modulators, tumor necrosis factor inhibitors, IL-6 inhibitors, or T-cell costimulation modulator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
82 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo plus Febuxostat

    Drug: Placebo · Drug: Febuxostat

  • Experimental
    AC-201

    AC-201 plus Febuxostat

    Drug: AC-201 · Drug: Febuxostat

Interventions

  • DrugPlacebo

    Placebo Capsule BID for 16 Weeks

    Also known as: PBO

  • DrugAC-201

    AC-201 50mg Capsule BID for 16 Weeks

  • Febuxostat 80 mg QD for 16 Weeks

    Also known as: ULT

06

What researchers measure

Primary outcomes

  1. Number of Gout Flares Per Subject

    Time frame: 16 weeks

07

Results

Posted Dec 1, 2014

Participant flow

Overall, 82 patients from 8 clinical centers participated in the study between 28 January 2013 to 04 September 2013.

Participant flow — Overall Study
MilestonePlaceboAC-201
Started4141
Completed3336
Not completed85
Withdrew: Adverse event31
Withdrew: Withdrawal by subject33
Withdrew: Lost to follow-up10
Withdrew: Protocol violation11

Outcome measures

PrimaryNumber of Gout Flares Per Subject
Time frame:
16 weeks
Reported as:
Least squares mean · flares
Number of Gout Flares Per Subject
flaresPlaceboAC-201
Number of Gout Flares Per Subject3.02 (2.51 to 3.64)2.45 (2.01 to 3.00)
Statistical analysis
  • Placebo vs AC-201 · Possion regression · p = 0.1356 · Risk ratio (rr): 0.81 · 95% CI 0.62 to 1.07

Adverse events

Collected over 16 weeks. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/41 (2.4%)11/41 (26.8%)
AC-201—0/41 (0%)10/41 (24.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboAC-201
Frequent Gout AttackMetabolism and nutrition disorders1/410/41
Most frequent other events
Most frequent other events
EventPlaceboAC-201
Blood CPK increasedInvestigations4/411/41
Hepatic function abnormalHepatobiliary disorders3/412/41
ALT increasedInvestigations3/410/41
TendonitisMusculoskeletal and connective tissue disorders1/412/41
Renal ImpairmentRenal and urinary disorders1/412/41
AnemiaBlood and lymphatic system disorders0/412/41
NasopharyngitisInfections and infestations0/412/41
Creatinine renal clearance decreasedInvestigations0/412/41

Baseline characteristics

A total of 82 subjects were randomized and received at least one dose of study medication (the Intent-to-Treat \[ITT\] Population). The ITT Population was used for baseline/demographic, disposition, and safety summaries. The ITT Population was the primary analysis set for efficacy analyses.

Age, Continuous
Age, Continuous(years)Placebo Capsule BIDAC-201 50mg Capsule BIDTotal
Mean43.6 ± 11.843.7 ± 12.643.6 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Capsule BIDAC-201 50mg Capsule BIDTotal
Female000
Male414182
08

Study locations

1 site
  • Veterans General Hospital
    Taipei, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2012
First posted
Oct 23, 2012
Start
Jan 2013
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Results first posted
Dec 1, 2014
Last update
May 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01712204
Lead sponsor
TWi Biotechnology, Inc.
Responsible party
Sponsor
First posted
Oct 23, 2012
Start date
Jan 2013
Primary completion
Sep 2013
Completion
Sep 2013
Results posted
Dec 1, 2014
Last update
May 22, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diacerein

Start the discussion